Skip to content
DataLookout
Start free
Menu

NCT06632860

A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors

StatusUnknown
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Primary completion date: Dec 20, 2024 to Dec 20, 2025
    • Study completion date: Dec 30, 2024 to Dec 30, 2025
    v3
  3. Eligibility criteria shortened, about 1 word
    • Study description shortened, about 15 words
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Tumor detection rate
Timeframe: through study completion, an average of half-year

Secondary (1)

standardized uptake value (SUV) of tumor

Arms and interventions

Experimental: 68Ga-TATE-RGD PET/ CT scanExperimental

About 30 patients with positive expression of somatostatin receptor SSTR2 and integrin receptor αvβ3 were included for PET imaging.

Drugs: 68Ga-TATE-RGD, 18-FDG

Sites

1 site in 1 country

  • Peking Union Medical College HospitalBeijing, Beijing Municipality, China